File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting

TitleLow-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting
Authors
KeywordsHodgkin lymphoma
low‐dose
nivolumab
pembrolizumab
refractory
Issue Date2020
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 2020, Epub 2020-08-12 How to Cite?
AbstractThe efficacy and safety of low‐dose anti‐PD1 antibodies in relapsed/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed/refractory cHL. In the pembrolizumab cohort (N = 11), who had failed a median of three (1–6) therapies (brentuximab vedotin [BV]: 91%; autologous hematopoietic stem cell transplantation [auto‐HSCT]: 18%), the overall response rate (ORR) by positron emission tomography–computed tomography was 100% (metabolic complete response [mCR]: 73%; partial response [PR]: 27%). Median cumulative dose for achieving best response was 400 (300–800) mg. Median progression‐free survival (PFS) was 35 months. Median overall survival (OS) was not reached. Adverse events (AEs) of grade 1–2 were observed in three patients. In the nivolumab cohort (N = 6), who had failed a median of three (2–6) therapies (BV: 50%; auto‐HSCT: 17%; allogeneic HSCT: 34%), the ORR was 100% (mCR: 67%; PR: 17%; indeterminate response: 17%). Median cumulative dose for achieving best response was 160 (160–360) mg. Median PFS was 33 months. Median OS was not reached. AEs of grade 1–2 were observed in four patients, two of whom had pre‐existing autoimmune conditions. Five patients with Epstein–Barr virus (EBV) positive Reed–Sternberg cells underwent monitoring of plasma EBV DNA, which became negative in four mCR patients but remained positive in one PR patient who died ultimately from refractory lymphoma. Low‐dose pembrolizumab and nivolumab were highly efficacious and safe in relapsed/refractory cHL. These observations have significant financial implications in resource‐constrained settings.
Persistent Identifierhttp://hdl.handle.net/10722/286199
ISSN
2019 Impact Factor: 2.832
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TSY-
dc.contributor.authorHwang, YY-
dc.contributor.authorKhong, PL-
dc.contributor.authorLeung, AYH-
dc.contributor.authorChim, CS-
dc.contributor.authorTse, EWC-
dc.contributor.authorKwong, YL-
dc.date.accessioned2020-08-31T07:00:33Z-
dc.date.available2020-08-31T07:00:33Z-
dc.date.issued2020-
dc.identifier.citationHematological Oncology, 2020, Epub 2020-08-12-
dc.identifier.issn0278-0232-
dc.identifier.urihttp://hdl.handle.net/10722/286199-
dc.description.abstractThe efficacy and safety of low‐dose anti‐PD1 antibodies in relapsed/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed/refractory cHL. In the pembrolizumab cohort (N = 11), who had failed a median of three (1–6) therapies (brentuximab vedotin [BV]: 91%; autologous hematopoietic stem cell transplantation [auto‐HSCT]: 18%), the overall response rate (ORR) by positron emission tomography–computed tomography was 100% (metabolic complete response [mCR]: 73%; partial response [PR]: 27%). Median cumulative dose for achieving best response was 400 (300–800) mg. Median progression‐free survival (PFS) was 35 months. Median overall survival (OS) was not reached. Adverse events (AEs) of grade 1–2 were observed in three patients. In the nivolumab cohort (N = 6), who had failed a median of three (2–6) therapies (BV: 50%; auto‐HSCT: 17%; allogeneic HSCT: 34%), the ORR was 100% (mCR: 67%; PR: 17%; indeterminate response: 17%). Median cumulative dose for achieving best response was 160 (160–360) mg. Median PFS was 33 months. Median OS was not reached. AEs of grade 1–2 were observed in four patients, two of whom had pre‐existing autoimmune conditions. Five patients with Epstein–Barr virus (EBV) positive Reed–Sternberg cells underwent monitoring of plasma EBV DNA, which became negative in four mCR patients but remained positive in one PR patient who died ultimately from refractory lymphoma. Low‐dose pembrolizumab and nivolumab were highly efficacious and safe in relapsed/refractory cHL. These observations have significant financial implications in resource‐constrained settings.-
dc.languageeng-
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182-
dc.relation.ispartofHematological Oncology-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectHodgkin lymphoma-
dc.subjectlow‐dose-
dc.subjectnivolumab-
dc.subjectpembrolizumab-
dc.subjectrefractory-
dc.titleLow-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting-
dc.typeArticle-
dc.identifier.emailChan, TSY: drtchan@hku.hk-
dc.identifier.emailHwang, YY: yyhwang@hku.hk-
dc.identifier.emailKhong, PL: plkhong@hku.hk-
dc.identifier.emailLeung, AYH: ayhleung@hku.hk-
dc.identifier.emailChim, CS: jcschim@hku.hk-
dc.identifier.emailTse, EWC: ewctse@hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hkucc.hku.hk-
dc.identifier.authorityKhong, PL=rp00467-
dc.identifier.authorityLeung, AYH=rp00265-
dc.identifier.authorityChim, CS=rp00408-
dc.identifier.authorityTse, EWC=rp00471-
dc.identifier.authorityKwong, YL=rp00358-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hon.2787-
dc.identifier.pmid32786092-
dc.identifier.scopuseid_2-s2.0-85089504248-
dc.identifier.hkuros313882-
dc.identifier.volumeEpub 2020-08-12-
dc.identifier.isiWOS:000560724400001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0278-0232-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats